Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy. (2014)

• Record Type: Journal Article
• Authors: Mirabile, Aurora; Celio, Luigi; Magni, Michele; Bonizzoni, Erminio; Gianni, Alessandro Massimo; Di Nicola, Massimo
• Is Part Of: Future oncology. Volume 10:Number 16(2014)
• Page Start: 2569
• Page End: 2578
• Publication Date: 2014
• Subjects: CINV -- dexamethasone -- high-dose chemotherapy -- nausea -- vomiting; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.14.132
• Languages: English
• ISSNs: 1479-6694

Abstract

ABSTRACT Aim: Efficacy of intermittent palonosetron dosing in patients undergoing multiple-day, high-dose chemotherapy (HDC) was investigated.Patients & methods: Fifty-eight patients received palonosetron (0.25 mg intravenous [iv.]) every other day plus daily dexamethasone (8 mg iv. twice daily) dosing. The primary end point was complete control (CC; no emesis, no rescue anti-emetics, and no more than mild nausea) in the overall acute-period (until 24 h after chemotherapy completion).Results: Acute-period CC occurred in 81% and 50% of patients receiving palonosetron and ondansetron (historical control cohort), respectively. Palonosetron (odds ratio [OR]: 4.37; p = 0.001) and a longer duration of HDC regimen (OR: 3.47; p = 0.011) independently predicted a better anti-emetic outcome.Conclusion: Palonosetron every other day plus daily dexamethasone is an effective anti-emetic coverage in patients undergoing HDC.